Sign In
Buy BONEX
Bonesupport Holding AB (publ) Earnings Calls
| Release date | Oct 23, 2025 |
| EPS estimate | kr0.85 |
| EPS actual | kr0.520 |
| EPS Surprise | -38.82% |
| Revenue estimate | 319.15M |
| Revenue actual | 294M |
| Revenue Surprise | -7.88% |
| Release date | Jul 15, 2025 |
| EPS estimate | kr0.95 |
| EPS actual | kr0.795 |
| EPS Surprise | -16.32% |
| Revenue estimate | 309.225M |
| Revenue actual | 284.425M |
| Revenue Surprise | -8.02% |
| Release date | Apr 24, 2025 |
| EPS estimate | - |
| EPS actual | kr0.156 |
| Revenue estimate | 276.2M |
| Revenue actual | 283.544M |
| Revenue Surprise | 2.66% |
| Release date | Feb 25, 2025 |
| EPS estimate | - |
| EPS actual | kr0.81 |
| Revenue estimate | 267.8M |
| Revenue actual | 257.01M |
| Revenue Surprise | -4.03% |
Last 4 Quarters for Bonesupport Holding AB (publ)
Below you can see how BONEX.ST performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | kr382.80 |
| EPS estimate | - |
| EPS actual | kr0.81 |
| Date | Price |
|---|---|
| Feb 19, 2025 | kr343.40 |
| Feb 20, 2025 | kr345.00 |
| Feb 21, 2025 | kr339.80 |
| Feb 24, 2025 | kr338.40 |
| Feb 25, 2025 | kr382.80 |
| Feb 26, 2025 | kr386.00 |
| Feb 27, 2025 | kr398.80 |
| Feb 28, 2025 | kr385.80 |
| Mar 03, 2025 | kr381.00 |
| 4 days before | 11.47% |
| 4 days after | -0.470% |
| On release day | 0.84% |
| Change in period | 10.95% |
| Release date | Apr 24, 2025 |
| Price on release | kr306.40 |
| EPS estimate | - |
| EPS actual | kr0.156 |
| Date | Price |
|---|---|
| Apr 16, 2025 | kr317.20 |
| Apr 17, 2025 | kr309.40 |
| Apr 22, 2025 | kr311.20 |
| Apr 23, 2025 | kr317.40 |
| Apr 24, 2025 | kr306.40 |
| Apr 25, 2025 | kr317.40 |
| Apr 28, 2025 | kr299.00 |
| Apr 29, 2025 | kr299.00 |
| Apr 30, 2025 | kr315.80 |
| 4 days before | -3.40% |
| 4 days after | 3.07% |
| On release day | 3.59% |
| Change in period | -0.441% |
| Release date | Jul 15, 2025 |
| Price on release | kr311.60 |
| EPS estimate | kr0.95 |
| EPS actual | kr0.795 |
| EPS surprise | -16.32% |
| Date | Price |
|---|---|
| Jul 09, 2025 | kr289.20 |
| Jul 10, 2025 | kr299.20 |
| Jul 11, 2025 | kr295.80 |
| Jul 14, 2025 | kr296.60 |
| Jul 15, 2025 | kr311.60 |
| Jul 16, 2025 | kr318.80 |
| Jul 17, 2025 | kr323.80 |
| Jul 18, 2025 | kr324.40 |
| Jul 21, 2025 | kr325.20 |
| 4 days before | 7.75% |
| 4 days after | 4.36% |
| On release day | 2.31% |
| Change in period | 12.45% |
| Release date | Oct 23, 2025 |
| Price on release | kr238.40 |
| EPS estimate | kr0.85 |
| EPS actual | kr0.520 |
| EPS surprise | -38.82% |
| Date | Price |
|---|---|
| Oct 17, 2025 | kr257.00 |
| Oct 20, 2025 | kr256.00 |
| Oct 21, 2025 | kr259.80 |
| Oct 22, 2025 | kr255.60 |
| Oct 23, 2025 | kr238.40 |
| Oct 24, 2025 | kr236.00 |
| Oct 27, 2025 | kr232.20 |
| Oct 28, 2025 | kr227.80 |
| Oct 29, 2025 | kr224.80 |
| 4 days before | -7.24% |
| 4 days after | -5.70% |
| On release day | -1.01% |
| Change in period | -12.53% |
Bonesupport Holding AB (publ) Earnings Call Transcript Summary of Q3 2025
BONESUPPORT delivered a strong Q3 2025 with net sales of SEK 294 million (24% reported growth; 34% growth at constant exchange rates). Growth was driven primarily by continued U.S. momentum for CERAMENT G (notably strong account recruitment and higher usage) and positive early traction in new segments: revision arthroplasty (publication of the CeraHip study) and an upcoming focused launch into spine (CERAMENT BVF in Q4 2025, regulatory dialogue for CERAMENT G spine planned with FDA in early 2026). Adjusted operating profit (excluding incentive effects) was SEK 79 million, giving an adjusted operating margin of ~27% (FX-adjusted margin near 29%). Reported operating result was SEK 65.4 million after FX headwinds of SEK 5.7 million. The company generated strong cash flow (operating cash flow SEK 71 million; cash balance SEK 379 million) and reiterated full-year guidance of sales growth above 40% in constant currencies. Management plans a Capital Markets Day in spring 2026 to outline key initiatives and capital deployment. Near-term considerations: continued U.S. dollar/SEK FX volatility affecting reported figures, seasonality and regional headwinds in some European markets (notably Germany and the U.K.), and the timing/pace of adoption in trauma versus elective revision arthroplasty. Management emphasizes continued investment in clinical evidence, medical education and targeted commercial expansion to drive longer-term adoption and health-economic acceptance.
